Results 61 to 70 of about 1,458 (171)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +2 more sources

EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer

Advanced Science, Volume 13, Issue 12, 27 February 2026.
This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv, Zihang Lin, Jiandong Sun, Yuhong Ye, Qibin Wu, Liangzhi Cai, Dabin Liu, Pengming Sun, Shie Wang   +8 more
wiley   +1 more source

Investigation into Tipifarnib as an anti-mitotic agent and Spindly as the mitotic target [PDF]

, 2021
The mitotic checkpoint is a failsafe mechanism for the cell to ensure correct chromosome segregation. The evolutionarily conserved kinetochore RZZ complex is an essential component of the mitotic checkpoint.
Smith, Joanne Dawn
core   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study

Cancer Medicine, Volume 15, Issue 1, January 2026.
Chemotherapy was not associated with improved survival in localized or metastatic CIC‐rearranged sarcoma. Optimizing local control remains essential, and novel systemic therapies are urgently needed. ABSTRACT Introduction CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults.
Talya Wittmann Dayagi, Hagit Peretz Soroka, Alannah Smrke, Rebecca J. Deyell, Xiaolan Feng, Sapna Oberoi, Shantanu Banerji, Jonathan Noujaim, Nicolas Prud'homme, Ramy Saleh, Omar Farooq Khan, Jonathan Willard Bush, Bilal Marwa, Geoffrey Watson, Caroline Holloway, Lingxin Zhang, Abha Anshu Gupta, Jack Brzezinski   +17 more
wiley   +1 more source

Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial [PDF]

International audienceAbstract Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory ...
Abbou, Samuel, Paoletti, Xavier, Defachelles, Anne, Sophie, Miah, Kowser, André, Nicolas, Hübschmann, Daniel, Defachelles, Anne Sophie, Mortimer, Peter G.S., Harttrampf, Anne C, Deloger, Marc, Marshall, Lynley, V, Aerts, Isabelle, Bautista, Francisco, Brard, Caroline, Gatz, Susanne, A, de Carli, Emilie, Rubino, Jonathan, Thebaud, Estelle, Marshall, Lynley V, Mortimer, Peter G S, Gatz, Susanne A; id_orcid, Rondof, Windy, Harttrampf, Anne, C, Rübsam, Marc, Godin, Robert, Vassal, Gilles, Geoerger, Birgit, Nebchi, Souad   +27 more
core   +1 more source

Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets

British Journal of Pharmacology, Volume 182, Issue 23, Page 5734-5747, December 2025.
Abstract Background and Purpose In order to significantly improve the therapeutic treatment of breast cancer, the exploration of underlying genetic and molecular differences is absolutely necessary. Here, our goal was to integrate mutational status of entire pathways to reveal molecular pathway interactions determining survival. Experimental Approach A
Máté Posta, Balázs Győrffy
wiley   +1 more source

Tumour Cell Size Control and Its Impact on Tumour Cell Function

Cell Proliferation, Volume 58, Issue 12, December 2025.
The regulatory mechanism of the size of tumour cells and its impact on the functions of tumour cells, as well as a summary of potential therapeutic targets for the corresponding mechanisms. ABSTRACT Cell size is an important component of cell morphological characteristics.
Min Zhou, Mei Zhou, Yang Jin
wiley   +1 more source

Supplementary Table S4 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

Summary of WEE1 inhibitor adavosertib clinical ...
Samuel Abbou (15119500), Susanne A. Gatz (17977394), Souad Nebchi (17977412), Xavier Paoletti (17977427), Marc Deloger (15061677), Lynley V. Marshall (15110912), Peter G.S. Mortimer (15112775), Gilles Vassal (17977436), Caroline Brard (15036380), Kowser Miah (17977433), Birgit Geoerger (14952291), Daniel Hübschmann (17977409), Robert Godin (17977430), Jonathan Rubino (17977400), Estelle Thebaud (17977418), Nicolas André (15119506), Isabelle Aerts (17977415), Francisco Bautista (17314452), Marc Rübsam (17977406), Emilie De Carli (17977421), Anne C. Harttrampf (17977397), Windy Rondof (17977403), Anne Sophie Defachelles (17977424)   +22 more
core   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, Volume 3, Issue 5, September 2025.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source